Details
Stereochemistry | UNKNOWN |
Molecular Formula | C14H16ClN3O4S2 |
Molecular Weight | 389.878 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 0 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NS(=O)(=O)C1=C(Cl)C=C2NC(NS(=O)(=O)C2=C1)C3CC4CC3C=C4
InChI
InChIKey=BOCUKUHCLICSIY-UHFFFAOYSA-N
InChI=1S/C14H16ClN3O4S2/c15-10-5-11-13(6-12(10)23(16,19)20)24(21,22)18-14(17-11)9-4-7-1-2-8(9)3-7/h1-2,5-9,14,17-18H,3-4H2,(H2,16,19,20)
Molecular Formula | C14H16ClN3O4S2 |
Molecular Weight | 389.878 |
Charge | 0 |
Count |
|
Stereochemistry | MIXED |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 4 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/10653443Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/14534329
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10653443
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/14534329
Cyclothiazide was presumably developed by Eli Lilly for the treatment of hypertension. It is believed that the drug, which belongs to the class of thiazide diuretics, exerts its action by inhibitin sodium reabsorption in the renal tubules. In 1993 it was discovered that cyclothiazide stimulates AMPA receptors thus inducing seizure behavior.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0070294 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10653443 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | ANHYDRON Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3912112
2.5 mg daily.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7751964
Cyclothiazide was added at concentration of 100 uM to rat medullary slices to test its effect on AMPA receptor channel desensitization.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:31:57 GMT 2025
by
admin
on
Mon Mar 31 18:31:57 GMT 2025
|
Record UNII |
P71U09G5BW
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
C03AA09
Created by
admin on Mon Mar 31 18:31:57 GMT 2025 , Edited by admin on Mon Mar 31 18:31:57 GMT 2025
|
||
|
WHO-VATC |
QC03AB09
Created by
admin on Mon Mar 31 18:31:57 GMT 2025 , Edited by admin on Mon Mar 31 18:31:57 GMT 2025
|
||
|
WHO-ATC |
C03AB09
Created by
admin on Mon Mar 31 18:31:57 GMT 2025 , Edited by admin on Mon Mar 31 18:31:57 GMT 2025
|
||
|
WHO-VATC |
QC03AA09
Created by
admin on Mon Mar 31 18:31:57 GMT 2025 , Edited by admin on Mon Mar 31 18:31:57 GMT 2025
|
||
|
NCI_THESAURUS |
C49185
Created by
admin on Mon Mar 31 18:31:57 GMT 2025 , Edited by admin on Mon Mar 31 18:31:57 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
P71U09G5BW
Created by
admin on Mon Mar 31 18:31:57 GMT 2025 , Edited by admin on Mon Mar 31 18:31:57 GMT 2025
|
PRIMARY | |||
|
1138
Created by
admin on Mon Mar 31 18:31:57 GMT 2025 , Edited by admin on Mon Mar 31 18:31:57 GMT 2025
|
PRIMARY | |||
|
218-859-7
Created by
admin on Mon Mar 31 18:31:57 GMT 2025 , Edited by admin on Mon Mar 31 18:31:57 GMT 2025
|
PRIMARY | |||
|
DTXSID3022871
Created by
admin on Mon Mar 31 18:31:57 GMT 2025 , Edited by admin on Mon Mar 31 18:31:57 GMT 2025
|
PRIMARY | |||
|
2259-96-3
Created by
admin on Mon Mar 31 18:31:57 GMT 2025 , Edited by admin on Mon Mar 31 18:31:57 GMT 2025
|
PRIMARY | |||
|
758431
Created by
admin on Mon Mar 31 18:31:57 GMT 2025 , Edited by admin on Mon Mar 31 18:31:57 GMT 2025
|
PRIMARY | |||
|
CHEMBL61593
Created by
admin on Mon Mar 31 18:31:57 GMT 2025 , Edited by admin on Mon Mar 31 18:31:57 GMT 2025
|
PRIMARY | |||
|
C004639
Created by
admin on Mon Mar 31 18:31:57 GMT 2025 , Edited by admin on Mon Mar 31 18:31:57 GMT 2025
|
PRIMARY | |||
|
CYCLOTHIAZIDE
Created by
admin on Mon Mar 31 18:31:57 GMT 2025 , Edited by admin on Mon Mar 31 18:31:57 GMT 2025
|
PRIMARY | |||
|
m4022
Created by
admin on Mon Mar 31 18:31:57 GMT 2025 , Edited by admin on Mon Mar 31 18:31:57 GMT 2025
|
PRIMARY | Merck Index | ||
|
761
Created by
admin on Mon Mar 31 18:31:57 GMT 2025 , Edited by admin on Mon Mar 31 18:31:57 GMT 2025
|
PRIMARY | |||
|
31448
Created by
admin on Mon Mar 31 18:31:57 GMT 2025 , Edited by admin on Mon Mar 31 18:31:57 GMT 2025
|
PRIMARY | |||
|
100000083757
Created by
admin on Mon Mar 31 18:31:57 GMT 2025 , Edited by admin on Mon Mar 31 18:31:57 GMT 2025
|
PRIMARY | |||
|
C65358
Created by
admin on Mon Mar 31 18:31:57 GMT 2025 , Edited by admin on Mon Mar 31 18:31:57 GMT 2025
|
PRIMARY | |||
|
2910
Created by
admin on Mon Mar 31 18:31:57 GMT 2025 , Edited by admin on Mon Mar 31 18:31:57 GMT 2025
|
PRIMARY | |||
|
22033
Created by
admin on Mon Mar 31 18:31:57 GMT 2025 , Edited by admin on Mon Mar 31 18:31:57 GMT 2025
|
PRIMARY | RxNorm | ||
|
SUB06864MIG
Created by
admin on Mon Mar 31 18:31:57 GMT 2025 , Edited by admin on Mon Mar 31 18:31:57 GMT 2025
|
PRIMARY | |||
|
DB00606
Created by
admin on Mon Mar 31 18:31:57 GMT 2025 , Edited by admin on Mon Mar 31 18:31:57 GMT 2025
|
PRIMARY | |||
|
3310
Created by
admin on Mon Mar 31 18:31:57 GMT 2025 , Edited by admin on Mon Mar 31 18:31:57 GMT 2025
|
PRIMARY | |||
|
1159008
Created by
admin on Mon Mar 31 18:31:57 GMT 2025 , Edited by admin on Mon Mar 31 18:31:57 GMT 2025
|
PRIMARY | |||
|
4167
Created by
admin on Mon Mar 31 18:31:57 GMT 2025 , Edited by admin on Mon Mar 31 18:31:57 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> INHIBITOR | |||
|
TARGET->POSITIVE ALLOSTERIC MODULATOR (PAM) |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |